These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37286910)

  • 1. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
    Toplak H; Bilitou A; Alber H; Auer J; Clodi M; Ebenbichler C; Fließer-Görzer E; Gelsinger C; Hanusch U; Ludvik B; Maca T; Schober A; Sock R; Speidl WS; Stulnig TM; Weitgasser R; Zirlik A; Koch M; Wienerroither S; Wolowacz SE; Diamand F; Catapano AL
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):364-374. PubMed ID: 37286910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
    Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D
    Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
    Katzmann JL; Becker C; Bilitou A; Laufs U
    PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.
    Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS
    J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Rubino J; MacDougall DE; Sterling LR; Hanselman JC; Nicholls SJ
    Atherosclerosis; 2021 Mar; 320():122-128. PubMed ID: 33514449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort.
    Blaum C; Brunner FJ; Goßling A; Kröger F; Bay B; Lorenz T; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Seiffert M; Waldeyer C
    Clin Ther; 2021 Sep; 43(9):1583-1600. PubMed ID: 34462126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
    Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
    J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
    Niman S; Rana K; Reid J; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):535-548. PubMed ID: 32166726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed Combination for the Treatment of Dyslipidaemia.
    Ferri N; Ruscica M; Santos RD; Corsini A
    Curr Atheroscler Rep; 2023 Oct; 25(10):691-699. PubMed ID: 37715044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.